PCSK9 and atherosclerosis: The silver lining seen throughout the changing landscape of cardiovascular medicine as a step toward better patient outcomes and a new front in the battle against ASCVD is the knowledge of the genetic basis behind PCSK9 inhibition and its effects on LDL‐C levels.